GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Equity-to-Asset

I-MAB (IMAB) Equity-to-Asset : 0.95 (As of Mar. 2025)


View and export this data going back to 2020. Start your Free Trial

What is I-MAB Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. I-MAB's Total Stockholders Equity for the quarter that ended in Mar. 2025 was $198.34 Mil. I-MAB's Total Assets for the quarter that ended in Mar. 2025 was $208.94 Mil.

The historical rank and industry rank for I-MAB's Equity-to-Asset or its related term are showing as below:

IMAB' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.17   Med: 0.81   Max: 0.95
Current: 0.95

During the past 8 years, the highest Equity to Asset Ratio of I-MAB was 0.95. The lowest was -1.17. And the median was 0.81.

IMAB's Equity-to-Asset is ranked better than
94.95% of 1485 companies
in the Biotechnology industry
Industry Median: 0.68 vs IMAB: 0.95

I-MAB Equity-to-Asset Historical Data

The historical data trend for I-MAB's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Equity-to-Asset Chart

I-MAB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Equity-to-Asset
Get a 7-Day Free Trial 0.89 0.81 0.71 0.66 0.95

I-MAB Quarterly Data
Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Sep20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.93 0.94 0.95 0.95

Competitive Comparison of I-MAB's Equity-to-Asset

For the Biotechnology subindustry, I-MAB's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


I-MAB's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where I-MAB's Equity-to-Asset falls into.


;
;

I-MAB Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

I-MAB's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Equity to Asset (A: Dec. 2024 )=Total Stockholders Equity/Total Assets
=201.16/212.68
=

I-MAB's Equity to Asset Ratio for the quarter that ended in Mar. 2025 is calculated as

Equity to Asset (Q: Mar. 2025 )=Total Stockholders Equity/Total Assets
=198.341/208.941
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


I-MAB  (NAS:IMAB) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


I-MAB Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of I-MAB's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


I-MAB Business Description

Traded in Other Exchanges
Address
2440 Research Boulevard, Suite 400, Rockville, MD, USA, 20850
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).